Last reviewed · How we verify
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings (BoostMe)
This is a phase IIb clinical trial investigating the non-inferiority of immune responses in children given two doses of measles vaccine at different timepoints. The study will randomise 450 children to 3 groups: group A will receive measles containing vaccine (MCV) at 6 and 12 months ; group B at 9 and 18 months; Group C at 6 and 18 months.
Details
| Lead sponsor | University of Oxford |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 450 |
| Start date | Wed Nov 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun May 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Measles
Interventions
- Licenced Measles-Rubella vaccine
Countries
Uganda